Atogepant
As of the edition of 20 October 2026, Atogepant is a small molecule: marketed, first approved in 2021 (US); acts on CALCRL; US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Qulipta
- First approved
- 28 September 2021 (US)
- Approvals on record
- 9 in 5 regions
- Holder of the most recent approval
- AbbVie; 2 holders in all
- Registered trials
- 26, 0 stopped early
- Disease areas
- Nervous system; Chemically induced; Ear, nose and throat; Mental health; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2035.
The last listed US drug-substance patent ends in 2035. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product15 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 15 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CALCRL | Calcitonin gene-related peptide type 1 receptor | Q16602 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 1 | 4 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 3 | 15 | 11 | 4 | 0 |
| Phase 4 | 3 | 1 | 2 | 0 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Originator, Applicant and Lead sponsor of trials | 2016 to now |